Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
investorenquiries@pharmaust.com+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Category Archives: Media

Small Caps – PharmAust appoints industry veteran to spearhead manufacturing ahead of critical MPL trial

MediaBy Nickholas Bahr18/04/2024

Stockhead – PharmAust inks approval from Macquarie University for Open-Label MND extension study

MediaBy Nickholas Bahr10/04/2024

Small Caps – PharmAust’s pioneering monepantel MND study receives HREC green light for final phase

MediaBy Nickholas Bahr10/04/2024

The West – How PharmAust is offering hope to patients with MND and ALS using veterinary drug monepantel

MediaBy Nickholas Bahr02/04/2024

Best Stocks – Revolutionizing ALS Treatment: New Findings Reveal Potential Game-Changer in Disease Management

MediaBy Nickholas Bahr19/03/2024

Small Caps – Australian biotech sector tipped for strong growth

MediaBy Nickholas Bahr19/03/2024

Stockhead – ‘Tide is turning for the healthcare sector’

MediaBy Nickholas Bahr18/03/2024

Small Caps – PharmAust eyes FDA orphan drug designation for monepantel after positive MND/ALS trial results

MediaBy Nickholas Bahr14/03/2024

Stockhead – PharmAust files groundbreaking MND/ALS clinical data with the FDA

MediaBy Nickholas Bahr14/03/2024

ALS News Today – Vet drug monepantel slows ALS, MND disease progression in trial

MediaBy Nickholas Bahr12/03/2024
←1234→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2025 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top